Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

While severe pain and burning are typical symptoms, tingling and buzzing sensations, along with numbness, can also be early ...

As temperatures rise and outdoor activities increase, Clark County officials are warning residents of pissbleAccording to the ...

A woman with a rare allergy to cold temperatures has revealed how even a few minutes outside in chilly weather can leave her ...

Picture: Supplied Their go-to packet of smokes now costs ... No doctor could figure out why I was getting chronic hives all ...